期刊文献+

齐拉西酮的合成 被引量:1

Synthesis of Ziprasidone
下载PDF
导出
摘要 以3-氯-1,2-苯并异噻唑和无水哌嗪为原料合成1-(1,2-苯并异噻唑-3-基)哌嗪(2),以6-氯-1,3-二氢-吲哚酮和氯乙酰氯为原料经Friedel-crafts酰化制备5-(2-氯乙酰基)-6-氯-1,3-二氢-吲哚酮(3),3经硼氢化钠和三氟乙酸还原制得5-(2-氯乙基)-6-氯-1,3-二氢-吲哚酮(4),2和4在碘化钠/碳酸钠的水溶液中缩合得到齐拉西酮(1),总收率50.5%(以3-氯-1,2-苯并异噻唑计,n/n)。齐拉西酮的结构经IR和1H NMR确证。 1,2-Benzoisothiazole-3-piperazine(2) was synthesized from 3-chloro-1,2-benzoisothiazole and piperazine.5-(2-Chloroacetyl)-6-chloro-indole ketone(3) was synthesized from 6-chloro-indole ketone and chloroacetyl chloride by Friedel-crafts acylation.Reduction of 3 by sodium borohydride gave 5-(2-chloroethyl)-6-chloro-indole ketone(4).Combination of 2 and 4 in aqueous solution of NaI / NaCO3 produced ziprasidone(1) in overall yield of 50.5%.The structures were confirmed by IR and 1H NMR.
出处 《精细化工中间体》 CAS 2010年第5期37-39,42,共4页 Fine Chemical Intermediates
关键词 抗精神病药 齐拉西酮 Friedel-crafts酰化 合成 antipsychotic drug ziprasidone Friedel-crafts acylation synthesis
  • 相关文献

参考文献11

  • 1梁海霞,李焕德.抗精神病新药齐拉西酮的药物动力学研究概况[J].中南药学,2007,5(3):254-258. 被引量:6
  • 2Gary R. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET [J]. Clin Psychiatry, 1999, 60 (10): 15-23.
  • 3Seeger T F, Seymour P A, Schmidt A W, et al. Ziprasidone (CP-88059) : a new anti- psychotic with combined dopamine and serotonin receptor antagonist activity [J]. J Pharmacol Exp Ther, 1995, 275 (1): 101-113.
  • 4Ghaemi S N, Hsu D J, Rosenquist K J, et al. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder [J]. Prog Neuropsy chopharmacol Biol psychiatry, 2006, 30 (2) : 209-213.
  • 5乔虹.非典型抗精神病药物的副作用[J].国外医学(药学分册),2005,32(1):26-28. 被引量:23
  • 6Rajiv T D. Anlipsychotics form theoy to practice: integrating clinical and basic data[J]. J Clin Psychiatry, 1999, 60 (18): 21.
  • 7Durgesh V, Nadkami, James F, et al. Improved process for the preparation of 6-chloro-5- (2-chloroethyl)oxindole [ J ]. Org -nic Process Research & Development, 2008, 12: 1 142- 1 145.
  • 8Fernandez H H, Trieschmann M E, Friedman J H. Treatment of psychosis in Par- kinson disease: safety considerations[J]. Drug Safe, 2003, 26 (9): 643-659.
  • 9Daniel E C.Side effect profiles of new antipsychotic agents [J]. J ClinPsychiatry, 1997, 57 (Suppl 11): 40-45.
  • 10Tanaka H, Ohno Y, Nakamure M. Localization and pharmacological characterization of [3H], perospirone-binding sites in rat brain[J]. Gen Pharmeal, 1998, 31 (1) : 159.

二级参考文献28

  • 1乔虹.非典型抗精神病药物的副作用[J].国外医学(药学分册),2005,32(1):26-28. 被引量:23
  • 2周远大,吴妍,何海霞.齐拉西酮片剂的人体药动学[J].中国新药与临床杂志,2006,25(2):95-97. 被引量:6
  • 3杨秋敏,周远大.单剂量肌肉注射甲磺酸齐拉西酮在健康人体的药动学研究[J].中国药房,2006,17(7):516-517. 被引量:2
  • 4郭志雄,王荷芳,辛春伟,陈立功.叶酸拮抗剂Alimta的合成[J].有机化学,2006,26(4):546-550. 被引量:8
  • 5[1]Seeger TF,Seymour PA,Schmidt Aw,et al.Ziprasidone(CP88059):a new antipsychotic with combined dopamine and serotonin receptor antagonist activity[J].J Pharmacol Exp Ther,1995,275(1):101-113.
  • 6[2]Ghaemi SN,Hsu DJ,Rosenquist KJ,et al.Extrapyramidal side effects with atypical neuroleptics in bipolar disorder[J].Prog Neuropsyehopharmacol Biod psychiatry,2006,30(2):209-213.
  • 7[4]Hamelin BA,Allard S,Laplante L,et al.The effect of timing of a standard meal on the pharmaeokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone[J].Pharmacotherapy,1998,18(1):9-15.
  • 8[5]Miceli JJ,Wilner KD,Hansen RA,et al.Single-and multipledose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers[J].Br J Clin Pharmacol,2000,49(Suppl 1):5-13.
  • 9[6]Wilner KD,Tensfeldt TG,Baris B,et al.Single-and multipledose pharmacokinetics of ziprasidone in healthy young and elderly volunteers[J].Br J Clin Pharmacol,2000,49(Suppl 1):15-20.
  • 10[7]Miceli JJ,Wilner KD,Swan SK,et al.Pharmacokinetics,safety,and tolerability of intramuscular ziprasidone in healthy volunteers[J].J Clin Pharmacol,2005,45(6):620-630.

共引文献48

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部